Guru Ownership Trend
Guru Analysis for Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 4 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $3.09 M.
Top institutional holders include Renaissance Technologies (RenTech) and Chuck Royce.
Institutional sentiment is currently Slightly Bearish. This is evidenced by a $1.78 M net outflow during the quarter.
Recent activity highlights Cliff Asness who increased their stake by 202.8%. Conversely, Chuck Royce reduced exposure by 51.1%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Entrada Therapeutics, Inc. (TRDA)
Major holders include Renaissance Technologies (RenTech) ($2.55 M), Chuck Royce ($1.53 M), Louis Moore Bacon ($1.33 M). According to the latest reported data, 4 tracked investment managers collectively hold approximately 507,422 shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $1.78 M, with 1 managers increasing positions and 3 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 1 fully exited TRDA. The total reported sell value was $2.46 M.
Yes, 0 managers opened new positions in TRDA, and 1 increased their existing holdings. The total reported buy value was $671,875.07.